261 related articles for article (PubMed ID: 34556244)
1. The Use of Biologics During the COVID-19 Pandemic.
Jones ME; Kohn AH; Pourali SP; Rajkumar JR; Gutierrez Y; Yim RM; Armstrong AW
Dermatol Clin; 2021 Oct; 39(4):545-553. PubMed ID: 34556244
[TBL] [Abstract][Full Text] [Related]
2. Biologics for chronic inflammatory skin diseases: an update for the clinician.
Yao Y; Ravn Jørgensen AH; Thomsen SF
J Dermatolog Treat; 2020 Mar; 31(2):108-130. PubMed ID: 30827126
[TBL] [Abstract][Full Text] [Related]
3. Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases.
Kaufman BP; Alexis AF
Curr Allergy Asthma Rep; 2018 Aug; 18(10):55. PubMed ID: 30171358
[TBL] [Abstract][Full Text] [Related]
4. Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic.
Yim RM; Singh I; Armstrong AW
Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147660
[TBL] [Abstract][Full Text] [Related]
5. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.
Ricardo JW; Lipner SR
Dermatol Ther; 2020 Sep; 33(5):e13687. PubMed ID: 32458536
[TBL] [Abstract][Full Text] [Related]
6. Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?
Patsatsi A; Kyriakou A
Clin Dermatol; 2021; 39(1):52-55. PubMed ID: 33972053
[TBL] [Abstract][Full Text] [Related]
7. Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic.
Kado S; Kamiya K; Kishimoto M; Maekawa T; Kuwahara A; Sugai J; Komine M; Ohtsuki M
J Dermatol; 2021 Dec; 48(12):1907-1912. PubMed ID: 34549456
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED-ZONE declaration.
Bragazzi NL; Riccò M; Pacifico A; Malagoli P; Kridin K; Pigatto P; Damiani G
Dermatol Ther; 2020 Jul; 33(4):e13508. PubMed ID: 32415727
[TBL] [Abstract][Full Text] [Related]
9. A Practical Guide to Using Biologics in Pediatric Dermatology.
George A; Lansang RP; Lansang P; Gooderham M
J Cutan Med Surg; 2024; 28(1):59-67. PubMed ID: 38229411
[TBL] [Abstract][Full Text] [Related]
10. Biologics in patients with skin diseases.
Veilleux MS; Shear NH
J Allergy Clin Immunol; 2017 May; 139(5):1423-1430. PubMed ID: 28477721
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in atopic dermatitis.
Li W; Man XY
Immunotherapy; 2022 Oct; 14(14):1149-1164. PubMed ID: 36046941
[TBL] [Abstract][Full Text] [Related]
12. Navigating Targeted Therapeutics in Dermatology: Biologics and Small Molecules.
Costello C; Maarouf M; Shi V
J Drugs Dermatol; 2018 Dec; 17(12):1330-1332. PubMed ID: 30586268
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab.
Ungar B; Glickman JW; Golant AK; Dubin C; Marushchak O; Gontzes A; Mikhaylov D; Singer GK; Baum D; Wei N; Sanin A; Gruenstein D; Lebwohl MG; Pavel AB; Guttman-Yassky E
J Allergy Clin Immunol Pract; 2022 Jan; 10(1):134-142. PubMed ID: 34737108
[TBL] [Abstract][Full Text] [Related]
14. Vaccination Recommendations for Psoriasis and Atopic Dermatitis Patients on Biologic Therapy: A Practical Guide.
Fan R; Cohen JM
Yale J Biol Med; 2022 Jun; 95(2):249-255. PubMed ID: 35782480
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
[TBL] [Abstract][Full Text] [Related]
16. Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.
Torres T; Puig L
Am J Clin Dermatol; 2020 Jun; 21(3):307-311. PubMed ID: 32277351
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
[TBL] [Abstract][Full Text] [Related]
18. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
19. Biological Therapies for Atopic Dermatitis: A Systematic Review.
Zhou S; Qi F; Gong Y; Zhang J; Zhu B
Dermatology; 2021; 237(4):542-552. PubMed ID: 33735876
[TBL] [Abstract][Full Text] [Related]
20. English version of Japanese guidance for biologics in treating atopic dermatitis.
Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
J Dermatol; 2023 Oct; 50(10):e311-e322. PubMed ID: 37650357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
